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Background: Opioids, antipsychotics and hypnotics are recommended for comfort care in dying. We studied their
prescription during the last 3 days in residents deceased in the long-term care facility (LTCF). Methods: In a
retrospective, cross-sectional survey in Belgium, England, Finland, Italy, the Netherlands and Poland, LTCFs,
selected by proportional stratified random sampling, reported all deaths over the previous 3 months. The nurse
most involved in the residents’ care reviewed the chart for opioid, antipsychotic and hypnotic prescription, cause
of death and comorbidities. Multivariable logistic regression was performed to adjust for resident characteristics.
Results: Response rate was 81.6%. We included 1079 deceased residents in 322 LCTFs. Opioid prescription ranged
from 18.5% (95% CI: 13.0–25.8) of residents in Poland to 77.9% (95% CI: 69.5–84.5) in the Netherlands, antipsych-
otic prescription from 4.8% (95% CI: 2.4–9.1) in Finland to 22.4% (95% CI: 14.7–32.4) in Italy, hypnotic prescription
from 7.8% (95% CI: 4.6–12.8) in Finland to 47.9% (95% CI: 38.5–57.3) in the Netherlands. Differences in opioid,
antipsychotic and hypnotic prescription between countries remained significant (P<0.001) when controlling for
age, gender, length of stay, cognitive status, cause of death in multilevel, multivariable analyses. Dying from
cancer showed higher odds for receiving opioids (OR 3.51; P<0.001) and hypnotics (OR 2.10; P=0.010).
Conclusions: Opioid, antipsychotic and hypnotic prescription in the dying phase differed significantly between
six European countries. Further research should determine the appropriateness of their prescription and refine
guidelines especially for LTCF residents dying of non-cancer diseases.
. .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . . .. . .. . .. . .. . .. . .. . .. . .. . .
Introduction
Long-term care facility (LTCF) residents in Europe evolve to ahighly dependent population with complex, often incurable
multi-morbidity.1 Consequently, palliative and terminal care
should be key components in LTCF care, with adequate pain- and
symptom-management as a priority.
Previous research documented a high prevalence of pain in LTCF
residents. In a cross-sectional study in three European countries, the
presence of pain varied between 32% and 57%. In nearly half of the
cases, pain was present every day and in over 50%, pain was rated
moderate-to-severe.2 A longitudinal study in the Netherlands
revealed pain prevalence up to 68%, with 41% of residents in
persistent pain.3 With regard to other symptoms, this study
indicated that agitation is the most common symptom, with
prevalence ranging from 57% to 71%.3
Pain treatment in a LTCFs is evolving, illustrated by an increase in
opioid prescription in LTCFs.4 Nevertheless, recent research estab-
lished undertreatment in residents with persistent pain.5 Especially
the group of residents with cognitive impairment, received less
opioid analgesics.6 In contrast, residents with dementia received
more psychotropic medication,7 although their use is recently
decreasing in the long-term care.4,8 Besides these studies about
central nervous agents in general, specific data about antipsychotic
and hypnotic prescription in LTCF residents near to death are rare
as some studies on medication use in LTCFs exclude dying
patients.2,4–7
In the last days of life, symptoms evolve rapidly. Sleep disturb-
ance, agitation and neuropsychiatric symptoms decrease, while pain,
feeding problems, breathing abnormalities, apathy and anxiety
increase.9 Pain prevalence up to 78%3 has been reported.
Recent guidelines concerning terminal care recommend the use of
opioids, hypnotics and antipsychotics to control pain, dyspnoea,
agitation, anxiety and delirium10 in the dying phase.
Existing studies examining the impact of the guidelines regarding
medication prescription at the end of life often focused on specific
populations such as cancer patients and patients with dementia or
are performed in acute care hospitals and palliative care settings.
Consequently, to date, little is known about the prescription of
opioids, hypnotics and antipsychotics in the last days of life in a
general LTCF population. The PACE study (PAlliative Care for the
Elderly), an EU-funded research project to assess quality of palliative
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care delivery in the European community‘s LTCFs, created the op-
portunity to conduct research in a larger, European population
sample and allowed epidemiological comparison of the factual
practice between participating countries. In this study, following
research questions were addressed: (i) what is the prevalence of
the prescription of opioids, antipsychotics and hypnotics in the
last 3 days of life in LTCFs’ residents in six European countries
and (ii) what factors are associated with this medication
prescription?
Methods
Study design, setting and participants
In six participating countries, Belgium, England, Finland, Italy, the
Netherlands and Poland a cross-sectional survey collected data on
deceased LTCF residents. Countries were selected in order to obtain
a good spread in geography, history of economic growth, healthcare
system and level of palliative care development. The study methods
are described in the published study protocol.11 In this article,
‘LTCF’ refers to a ‘collective institutional settings where care, on-
site provision of personal assistance of daily living, and on-site or
off-site provision of nursing and medical care, is provided for older
people who live there, 24 hours a day, 7 days a week, for an
undefined period of time’,. LTCFs were identified using proportional
stratified random sampling, to guarantee nation-wide representa-
tiveness. Participating LTCFs reported all residents who died in a
retrospective 3-month period, prior to the researchers visit to the
LTCF. For this survey, we included residents who died in their LTCF
and of whom the nurses’ questionnaire was completed.
Data collection
Through an anonymized procedure, structured after-death question-
naires, regarding each deceased resident were sent to the treating
physician, the nurse or care assistant most involved in the
resident’s care and the LTCF management.
Measurements
Demographic data and length of stay were extracted from the LTCF
managements questionnaire regarding the deceased resident; LTCF
characteristics from the LTCF managements questionnaire regarding
their LTCF. In this study, ‘LTCF type’ refers to the staffing structure,
depending on whether physicians and nurses are on-site or off-site.
In every participating country, we found LTCFs with nurses on site
24/7, and physicians off-site. In Italy, the Netherlands and Poland,
some LTCFs reported physicians and nurses on-site. LTCFs with on-
site care assistants and off-site nurses and physicians only
participated in the study in England.11
Based on the nursing records, the nurses provided information on
the residents prescriptions, functional and cognitive status, dementia
status and cause of death. Based on a list of available medications per
country, the nurses executed a chart review to check whether or not
opioids (e.g. morphine, oxycodone, hydromorphone, fentanyl,
buprenorphine, tramadol), antipsychotics (e.g. haloperidol,
risperdone, olanzapine, clotiapine) and hypnotics (e.g. midazolam,
oxazepam, lorazepam, lormetazepam, zopiclone, zolpidem,
zaleplon) had been prescribed to the resident in the last 72 hours
of life. Functional and cognitive status was estimated by the Bedford
Alzheimer Nursing Severity scale (BANS-S), a rating scale,
comprising cognitive and functional items, developed for grading
severity of dementia.12 Higher scores indicate higher functional
disability and dependency. In the database, a resident ‘with
dementia’ was defined as a resident to whom the nurse and/or the
physician referred to as a resident with dementia. Cause of death was
determined by means of a predefined checklist. The list of questions
of the nurses’ PACE-questionnaire, used in this paper (see
Supplementary appendix).
Statistical analysis
Descriptive statistics were provided per country as percentages (for
categorical outcomes) and mean and SD (for continuous outcomes).
Differences in residents’ and LTCFs’ characteristics between
countries were explored by means of normal, multinomial and
logistic regression, depending if the dependent variable was
continuous, categorical or binary. Second, the estimated
percentage and corresponding 95% CI of opioid, antipsychotic
and hypnotic prescription was estimated using a mixed logistic
regression model with LTCF as random factor and country as
fixed factor. Lastly, to assess factors associated with medication pre-
scription, a multilevel binary logistic regression model was built.
All residents’ and LTCFs’ characteristics, showing a difference in
opioid use prevalence with P < 0.100 in univariable multilevel
analysis were included in a stepwise backward model building
procedure, with P < 0.01 as boundary for statistical significance.
Country was included as fixed effect to compare data between
countries, LTCF was defined as a random effect. Other fixed
effects were age category, gender, length of stay, BANS-S score,
dementia status and cause of death on resident level and staffing
structure on LTCF level. The resulting model was applied to explore
associations with prevalence of antipsychotic and hypnotic use.
Associated factors were calculated for the entire survey population
and per country. The estimated variance between LTCFs was used to
calculate the adjusted intraclass correlation coefficients on the LTCF
level to explore variation between LTCFs.13 Statistical analyses were
performed in SPSS 23.
Results
The PACE database contains data from 1707 deceased residents in
322 LTCFs. The nurses response rate was 81.6% (ranging from
54.2% in England to 95.1% in Finland). For this survey, we
excluded 323 residents of whom we did not receive the nurses’ ques-
tionnaire and 305 residents who died outside their LTCF, resulting
in a study sample of 1079 residents, deceased in their LTCF.
Residents’ and LTCFs’ characteristics
As shown in table 1, significant differences in LTCF type were
identified. The deceased residents differed between countries by
age, length of stay, BANS-S score, prevalence of dementia status
and cancer versus non-cancer cause of death. Compared with
other countries, LTCF residents were younger and had a shorter
stay in Poland, where the cause of death was predominantly cardio-
vascular and cerebrovascular disease. Polish residents also had the
highest BANS-S score, reflecting a higher dependency rate in daily
life activities. Finnish LTCF residents had the highest percentage of
dementia.
Medication prescription prevalence
The estimated prevalence of opioid, antipsychotic and hypnotic pre-
scription in the last 3 days of life (figure 1) differed (P< 0.001)
between countries. Opioid prescription varied from 18.5% in
Poland to 77.9% in the Netherlands. Antipsychotic prescription
varied from 4.8% in Finland to 22.4% in Italy. Hypnotic prescrip-
tion ranged from 7.8% in Finland to 47.9% in the Netherlands.
Factors associated with medication prescription
After statistical adjustment for LTCF type and resident’s character-
istics, odds of opioid prescription in the last 3 days of life were
significantly higher in all countries than in Poland, with exception
of Italy (table 2). ORs ranged from 9.46 in Finland (95% CI: 4.58–
19.52) to 23.11 in England (95% CI: 7.12–75.4 Opioid prescription
was associated with the BANS-S score (OR 1.07; 95% CI: 1.03–1.11),
reflecting an increase in opioid prescription for residents with more
2 European Journal of Public Health
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severe physical disability. Odds of opioid prescription was 3.5 times
higher for residents dying of cancer (OR 3.51; 95% CI: 1.83–6.72)
compared with residents dying of non-cancer causes.
Odds of antipsychotics were about a fourth in Finland (OR 0.23;
95% CI: 0.09–0.56) in comparison to Poland.
Odds of hypnotic prescription were about a fourth in Finland (OR
0.24; 95% CI: 0.11–0.53) though were higher in the Netherlands (OR
3.80; 95% CI: 1.98–7.30) compared with Poland. Odds of hypnotic
prescription were higher (OR 2.10; 95% CI: 1.20–3.67) for residents
dying of cancer, than for residents dying of other causes. In this
study, the dementia status did not show any significant association
with opioid, antipsychotic and hypnotic prescription.
The intra-class correlation coefficient within the level of LTCFs
was 14.7 for opioid prescription, meaning that about 15% of the
variation was due to factors of the LTCF. The intra-class correlation
coefficient within the level of the LTCF was 9% for antipsychotic and
13% for hypnotic prescription.
Factors associated with medication prescription within
a country
We found associations between opioid prescription and dying of
cancer within some countries. Compared with residents, deceased
of non-cancer diseases, odds for receiving opioids amongst residents
dying of cancer were 14.28 in Italy (95% CI: 2.26–90.3) 8.96 in
Poland (95% CI: 1.6–49.40; P= 0.012). We found no other signifi-
cant associations for cancer. Other variables did not show significant
associations with medication prescription in any of the countries
studied, which could be explained by small sample sizes per country.
Discussion
Principal findings
In our study, we found significant differences between six European
countries in opioid, psychotic and hypnotic prescriptions in the last
3 days of life of LTCF residents. The most striking differences were
found in opioid prescription estimated percentages, ranging from
18.5% in Poland to 77.9% in the Netherlands. Low prevalence of
antipsychotic (4.8%) and hypnotic (7.8%) prescription in Finland
was also noteworthy. Differences in medication prescription between
countries stood firm after multiple statistical adjustment, meaning
that LTCF type or residents characteristics alone do not explain these
differences. Country appears as the most important determinant for
the prevalence of opioid, antipsychotic and hypnotic prescription in
the last 3 days of life in LTCFs. Dying of cancer triples the odds of
opioid prescription and doubles the odds of hypnotic prescription in
LTCFs’ residents’ end of life.
Relation to other studies and possible explanations
Opioid prescription prevalence in the last days of life of 60%14 and
70%15,16 is regularly documented. Klapwijk17 even described opioid
prescription prevalence up to 100% of LTCF residents of whom
death was expected. Also in our study, the Netherlands had the
highest opioid prescription prevalence. The low prevalence of
opioid prescription in Italy (31.7%) and Poland (19.6%) is
remarkable, but consistent with other research. In both countries,
opioid prescription per capita was found to be lower than in other
West-European countries.18 Opioid prescription in LTCFs may
reflect the low prevalence in both countries7,19 in general.
Although death is not often easily predictable in LTCF residents,
prevalence of pain increases to 78% and shortness of breath to
52% in the last week of life.16 Taken into account the high
prevalence of pain in LTCF residents, low opioid prescription
Table 1 Comparison of resident characteristics between countries
Country Poland Italy Finland England Belgium The Netherlands P value
n 234 144 196 72 237 196
LTCF type
Type of LTCF where residents died
Physicians and nurses offsite 0% 0% 0% 43.1% 0% 0% <0.001a
Physicians off-site, nurses on site 32.5% 75.2% 100% 56.9% 100% 38.9%
Physicians and nurses on site 67.5% 24.8% 0% 0% 0% 61.1%
Resident characteristics
Residents’ gender (% female) 65.5 66.7 68.6 74.6 63.8 67.0 0.668b
Residents’ age in years
90 22.4% 27.8% 36.4% 46.0% 43.9% 40.9% 0.036a
80–89 46.1% 55.5% 52.3% 38.1% 45.7% 42.6%
<80 31.5% 16.7% 11.3% 15.9% 10.4% 16.5%
Residents’ mean age (SD) 81.3 (11.0) 85.6 (7.5) 86.6 (8.2) 88.3 (7.3) 87.5 (7.5) 86.9 (8.1) <0.001c
Length of stay in years (SD) 1.8 (3.0) 2.3 (3.2) 2.7 (2.9) 2.5 (3.0) 3.4 (3.6) 2.9 (3.2) 0.002c
Mean total BANS-S scored (SD) 22.4 (4.3) 21.9 (3.9) 20.0 (3.8) 17.7 (3.9) 19.1 (4.8) 18.2 (4.6) <0.001c
Resident with dementiae 67.7% 79.1% 87.2% 60.3% 66.4% 65.9% <0.001b
Cause of death
Non-cancer 95.2% 89.8% 91.9% 80.0% 89.7% 91.1%
Cancer 4.8% 10.2% 8.1% 20.0% 10.3% 8.9% 0.050b
a: Calculated with multinomial logistic regression.
b: Calculated with binary logistic regression.
c: Calculated with linear regression.
d: BANS-S. Seven-item scale, scores range 7–24, higher scores indicate higher functional disability and dependency.
e: In this survey, a resident ‘with dementia’ is a resident which is designated as ‘suffering from dementia’ by the nurse and/or the physician.
Figure 1 Estimated percentage of residents with opioid, anti-
psychotic and hypnotic prescription in last 3 days of life
Opioid, antipsychotic and hypnotic use 3
D
ow
nloaded from
 https://academ
ic.oup.com
/eurpub/advance-article-abstract/doi/10.1093/eurpub/cky196/5115229 by G
hent U
niversity user on 08 O
ctober 2018
prevalence in Italy and Poland could be questioned, since guidelines
consider opioids as a as an effective treatment for pain symptoms
during the last days of life and also recommend opioids to treat
dyspnoea in the last days of life.10,20
Low opioid availability and prescription in Poland was described
in an EU report.21,22 The ATOME group identified legislative
barriers to opioid consumption in Poland: palliative care support
initiatives are almost exclusively consulted for cancer patients to
whom every cancer treatment is declined due to the feeble
prognostic. Moreover, complete reimbursement of opioids was ex-
clusively entitled to cancer patients, whereas other patients receive
only 30% reimbursement in Poland. The low frequency of medical
consultations could be an additional factor. Visits of the treating
physician are planned every fortnight or even once monthly. As
symptom burden,17 and hence, the need for treatment15 quickly
evolves in the last days of life, this frequency is too low to
provide effective response. Popular convictions and attitudes are
another barrier to effective opioid use. The ATOME report22
already defined fear of opioids as an important factor. This fear
and negative image of opioids is wide spread in the Polish
society, even amongst healthcare professionals. In Italy, the
reluctance to communicate openly23 about end of life and dying
could explain the low opioid prescription, since opioids, by
mistake, still might be seen as life-shortening23 or causing respira-
tory depression.24 For the same reason, family members often
oppose opioid use,23 although cancer seemed to be a potent
driver of opioid prescription, as opposed to non-malignant
conditions.
Antipsychotic prescription prevalence in LTCF end-of-life care is,
in our findings, lower than published in other research,15 and was
remarkably low in Finland, which is consistent with another study.
In Finland, there is a trend to decrease central nervous agents in
patients, especially with dementia, as described by Pitkala.4
The wide variation in hypnotic prescription prevalence between
participating countries might reflect different clinical practices
regarding hypnotic prescription.
In our study, we found no association between dementia and
medication prescription. Poorer analgesic treatment for persons
with dementia has been documented,25 but for opioid treatment, a
shift in awareness has been noticed in the last decade.26,27 Our
findings might be considered confirmatory of this trend,
suggesting that residents with dementia are as likely as those
without to receive opioids. Moreover, in Finland, the increase in
opioid prescription is established concomitantly with the decrease
in psychotropic medication.4
Residents dying of cancer are 3.5 times more likely to receive
opioids, compared with residents who died of other diseases.
Opioid treatment for non-malignant pain remains a controversial
issue.28 Guidelines advise caregivers to remain vigilant about long-
term side effects and opioid dependence.29 As a consequence,
physicians and their patients feel insecure about misuse and
addiction30 and tend to have a wait-and-see approach towards
opioids. Physicians often doubt the objectivity of non-malignant
pain complaints, the appropriateness of opioid therapy and feel
less confident and more concerned to prescribe opioids for non-
malignant pain, compared with cancer-related pain. They attribute
their reluctance to a lack of knowledge and training.31 This may
explain why the discrepancy in opioid prescription between cancer
pain and non-malignant pain is more explicit in countries with
lower palliative care knowledge.
Strengths and limitations
To our knowledge, this is the first European cross-country study
concerning opioid, antipsychotic and hypnotic prescription in the
dying phase in LTCF residents. The large population sample, the
cross-country survey design, the focus on all LTCF deaths,
Table 2 Resident and LTCF characteristics associated with medication prescription in the last 3 days of life
Opioids Antipsychotics Hypnotics
OR (95% CI) OR (95% CI) OR (95% CI)
Country
The Netherlands 21.22 (10.37–43.39) 0.56 (0.27–1.19) 3.80 (1.98–7.30)
Belgium 14.68 (6.92–31.11) 0.79 (0.38–1.64) 1.71 (0.86–3.39)
England 23.11 (7.12–75.04) 0.78 (0.24–2.58) 3.42 (1.23–9.48)
Finland 9.46 (4.58–19.52) 0.23 (0.09–0.56) 0.24 (0.11–0.53)
Italy 1.76 (0.83–3.73) 1.22 (0.59–2.50) 1.14 (0.55–2.36)
Poland Ref. Ref. Ref.
Type of LTCF
Physicians and nurses off-site 0.37 (0.08–1.65) 1.40 (0.26–7.47) 1.10 (0.27–4.47)
Physicians off-site, nurses on site 0.99 (0.54–1.82) 1.24 (0.66–2.32) 1.87 (1.05–3.32)
Physicians and nurses on site Ref. Ref. Ref.
Resident’s gender
Female 1.10 (0.78–1.57) 0.85 (0.55–1.30) 0.93 (0.65–1.32)
Male Ref. Ref. Ref.
Resident’s age in years
90 1.00 (0.59–1.68) 0.76 (0.40–1.42) 0.56 (0.33–0.93)
80–89 1.12 (0.69–1.80) 1.20 (0.68–1.09) 0.93 (0.58–1.48)
<80 Ref. Ref. Ref.
Length of stay in years 0.94 (0.89–0.99) 1.000 (0.99–1.01) 0.94 (0.89–1.00)
Total BANS-S scorea 1.07 (1.03–1.11) 0.98 (0.93–1.02) 0.99 (0.95–1.02)
Resident with dementiab
Yes 0.96 (0.65–1.40) 0.96 (0.60–1.54) 0.84 (0.57–1.24)
No Ref. Ref. Ref.
Cause of death
Cancer 3.51 (1.83–6.72) 1.65 (0.86–3.13) 2.10 (1.20–3.67)
Non-cancer Ref. Ref. Ref.
Multilevel multivariable logistic regression.
Opioids: 917 included, 162 missing. Antipsychotics: 917 included, 162 missing. Hypnotics: 908 included, 171 missing.
a: BANS-S. Seven-item scale, scores range 7–24, higher scores indicate higher functional disability and dependency.
b: In this survey, a resident ‘with dementia’ is a resident which is designated as ‘suffering from dementia’ by the nurse, the physician or
both.
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regardless of cause of death and the high response rate are the main
strengths of this study. Nevertheless, some limitations have to be
acknowledged. We excluded 305 residents who died outside the
LTCF. Some of them were transferred to the hospital for further
diagnosing, for symptom control, because an exacerbation of their
general condition or because a life-threatening situation occurred.
This exclusion may lead to a bias and underestimate the medication
use in the dying phase. Second, the study only provided dichotom-
ous data on medication prescription: whether or not, an opioid,
antipsychotic or hypnotic was prescribed in the last three days of
life. We had no information about the indication, the prescribed
dosage nor the prescription date. Higher dose of opioid prescription
is not an unambiguous proof of improved treatment since overuse
or misuse of opioids cannot be excluded based on the data we have
got available. The link between the residents’ symptom burden and
drug prescription needs further consideration. Whether or not death
was expected, is not taken into account in our study. Since this
information was provided by the physicians’ questionnaire, with a
lower response rate (68, 3%), we did not take it into consideration to
avoid drop-out. Finally, although the response rate differs between
countries, it was only the low response rate in England which
hampers the generalisation in England. Furthermore, the non-re-
spondents analysis for care staff showed no significant differences
in the residents demographic and clinical characteristics and the stay
in the nursing home between residents with and without
participating nursing staff.
Implications for clinicians and policymakers
Our study pointed to the existence of important differences in
medication prescription in the last three days of life of LTCF
residents between participating European countries. Further
research is needed to explain these differences. Disseminating
correct information on the indication of use to the broad public
and developing palliative care knowledge amongst health care pro-
fessionals remain important points of action.
The existing difference in medication prescription between cancer
and non-cancer patients is a concern both for clinical practice and
research. In palliative care, clinicians should focus on the symptoms
as such, and aim to improve the patients comfort, regardless of the
underlying cause. Symptom relieve is not justified because a patient
has cancer, but because he or she is suffering. In any case, palliative
guidelines need to be developed or refined for older patients and
those dying from non-cancer diseases, taking the multi-morbidity,
the specific responsiveness and vulnerability for side effects of older
patients into account.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
 We found large differences between European countries in
opioid, antipsychotic and hypnotic prescription in end-of-
life in LTCFs.
 These differences remained significant after statistical
adjustment for LTCF type and resident characteristics.
 Further research is needed to refine palliative care for
European older citizens, dying in LTCFs, especially for
those, dying from non-cancer diseases.
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